{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:44:05Z","timestamp":1784198645135,"version":"3.55.0"},"reference-count":30,"publisher":"BMJ","issue":"23","funder":[{"name":"Society for Mucopolysaccharide Diseases"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2019,7,3]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fabry disease is a treatable X-linked condition leading to progressive cardiomyopathy, arrhythmia and premature death. Atrial and ventricular arrhythmias contribute significantly to adverse prognosis; however, guidance to determine which patients require cardiovascular implantable electronic devices (CIEDs) is sparse. We aimed to evaluate indications for implantation practice in the UK and quantify device utilisation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this retrospective study, we included demographic, clinical and imaging data from patients in four of the largest UK Fabry centres. Ninety patients with Fabry disease were identified with CIEDs implanted between June 2001 and February 2018 (FD-CIED group). To investigate differences in clinical and imaging markers between those with and without devices, these patients were compared with 276 patients without a CIED (FD-control).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the FD-CIED group, 92% of patients with permanent pacemakers but only 28% with implantable cardioverter-defibrillators had a class 1 indication for implantation. A further 44% of patients had defibrillators inserted for primary prevention outside of current guidance. The burden of arrhythmia requiring treatment in the FD-CIED group was high (asymptomatic atrial fibrillation:<\/jats:p>\n                  <jats:p>29%; non-sustained ventricular tachycardia requiring medical therapy alone: 26%; sustained ventricular tachycardia needing anti-tachycardia pacing\/defibrillation: 28%). Those with devices were older, had greater LV mass, more scar tissue and larger atrial size.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Arrhythmias are common in Fabry patients. Those with cardiac devices had high rates of atrial fibrillation requiring anticoagulation and ventricular arrhythmia needing device treatment. These are as high as those in hypertrophic cardiomyopathy, supporting the need for Fabry-specific indications for device implantation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2019-315229","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T17:25:14Z","timestamp":1566667514000},"page":"1825-1831","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy"],"prefix":"10.1136","volume":"105","clinical-trial-number":[{"clinical-trial-number":"nct03199001","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2472-5538","authenticated-orcid":false,"given":"Ravi","family":"Vijapurapu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK"},{"name":"Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK"},{"name":"Department of Endocrinology, Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarekegn","family":"Geberhiwot","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Queen Elizabeth Hospital Birmingham, Birmingham, UK"},{"name":"Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jovanovic","sequence":"additional","affiliation":[{"name":"Mark Holland Metabolic Unit, Salford Royal Hospitals NHS Trust, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanat","family":"Baig","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK"},{"name":"Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK"},{"name":"Department of Endocrinology, Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Nordin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kozor","sequence":"additional","affiliation":[{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Leyva","sequence":"additional","affiliation":[{"name":"Aston Medical Research Institute, Aston Medical School, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-9812","authenticated-orcid":false,"given":"Dipak","family":"Kotecha","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK"},{"name":"Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Wheeldon","sequence":"additional","affiliation":[{"name":"South Yorkshire Cardiothoracic Centre, Northern General Hospital, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Deegan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary A","family":"Rusk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Barts Heart Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A","family":"Hughes","sequence":"additional","affiliation":[{"name":"Lysosomal Storage Disorder Unit, Royal Free London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Woolfson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Salford Royal Hospitals NHS Trust, Salford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P","family":"Steeds","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK"},{"name":"Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"key":"2025100705503716000_105.23.1825.1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-4-200302180-00014"},{"key":"2025100705503716000_105.23.1825.2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry's disease","volume":"372","author":"Zarate","year":"2008","journal-title":"The Lancet"},{"key":"2025100705503716000_105.23.1825.3","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcq117"},{"key":"2025100705503716000_105.23.1825.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm153"},{"key":"2025100705503716000_105.23.1825.5","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2008.065904"},{"key":"2025100705503716000_105.23.1825.6","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012428009627"},{"key":"2025100705503716000_105.23.1825.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.114.002569"},{"key":"2025100705503716000_105.23.1825.8","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306782"},{"key":"2025100705503716000_105.23.1825.9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/clc.22047","article-title":"Arrhythmias in Fabry cardiomyopathy","volume":"35","author":"Acharya","year":"2012","journal-title":"Clin Cardiol"},{"key":"2025100705503716000_105.23.1825.10","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12077"},{"key":"2025100705503716000_105.23.1825.11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am J Cardiol"},{"key":"2025100705503716000_105.23.1825.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.11.018"},{"key":"2025100705503716000_105.23.1825.13","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace"},{"key":"2025100705503716000_105.23.1825.14","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eur267"},{"key":"2025100705503716000_105.23.1825.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"2025100705503716000_105.23.1825.16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/jhg.2016.52","article-title":"Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis","volume":"61","author":"Seo","year":"2016","journal-title":"J Hum Genet"},{"key":"2025100705503716000_105.23.1825.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht150"},{"key":"2025100705503716000_105.23.1825.18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv316"},{"key":"2025100705503716000_105.23.1825.19","doi-asserted-by":"crossref","unstructured":"Nordin S , Kozor R , Medina-Menacho K , et al . Proposed Stages of Myocardial Phenotype Development in Fabry Disease. JACC Cardiovasc Imaging 2018. doi:doi:10.1016\/j.jcmg.2018.03.020. [Epub ahead of print: 16 May 2018].","DOI":"10.1016\/j.jcmg.2018.03.020"},{"key":"2025100705503716000_105.23.1825.20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/08035320600618825","article-title":"The Mainz severity score index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease","volume":"95","author":"Beck","year":"2006","journal-title":"Acta Paediatr"},{"key":"2025100705503716000_105.23.1825.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2005.10.005"},{"key":"2025100705503716000_105.23.1825.22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv316"},{"key":"2025100705503716000_105.23.1825.23","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181bb05bb"},{"key":"2025100705503716000_105.23.1825.24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","article-title":"Arrhythmia and clinical cardiac findings in children with Anderson-Fabry disease","volume":"120","author":"Wilson","year":"2017","journal-title":"Am J Cardiol"},{"key":"2025100705503716000_105.23.1825.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.06.019"},{"key":"2025100705503716000_105.23.1825.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.07.741"},{"key":"2025100705503716000_105.23.1825.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/615218","article-title":"Fabry disease and early stroke","volume":"2011","author":"Feldt-Rasmussen","year":"2011","journal-title":"Stroke Res Treat"},{"key":"2025100705503716000_105.23.1825.28","first-page":"1","article-title":"Cardiac manifestation of Fabry disease: from hypertrophic cardiomyopathy to early diagnosis and treatment in patients without left ventricular hypertrophy","volume":"4","author":"Fernandez","year":"2016","journal-title":"J Inborn Err Metab"},{"key":"2025100705503716000_105.23.1825.29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"2025100705503716000_105.23.1825.30","doi-asserted-by":"crossref","unstructured":"Vijapurapu R , Baig S , Wheeldon N , et al . P1017A national study evaluating cardiac device implantation and usage in patients with Fabry disease. Eur Heart J 2018;39(suppl_1).doi:10.1093\/eurheartj\/ehy564.P1017","DOI":"10.1093\/eurheartj\/ehy564.P1017"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2019-315229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:50:45Z","timestamp":1759841445000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2019-315229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":30,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2019,11,13]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/heartjnl-2019-315229"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2019-315229","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]}}}